Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions?
Antimuscarinic drugs are generally thought to exert their therapeutic action on detrusor overactivity by reducing the ability of the detrusor muscle to contract. We review currently available published data to establish whether there is any evidence to support this contention. Using a PubMed data search, only 14 original articles (including two abstracts) were found that contained cystometric data for both filling and voiding phases and where the actions of antimuscarinic drugs have been reported in detail. These articles were separated into three groups dealing with neuropathic patients (three papers), patients with idiopathic overactive bladder (four papers) and a group whose aetiology was unclear (seven papers). Variables relating to bladder function during the filling phase (time of first desire to void, time to first unstable contraction, and bladder capacity) were identified. Similarly, variables relating to voiding were identified and compared (e.g. maximum detrusor pressure and detrusor pressure at maximum flow rate). The antimuscarinic drugs have a clearly significant effect on sensations of urge, time to first sensation to void, maximum bladder capacity, decrease in voiding frequency and reduction in incontinence episodes. However, only one article (studying neuropaths) reported a significant reduction of the variables associated with detrusor contraction. The remaining four studies (idiopaths/not stated), reported no change in bladder contractility with antimuscarinic drugs. Thus the available data do not support the conclusion that antimuscarinic drugs at doses used in current clinical practice exert their therapeutic action by inhibiting detrusor contractility, but they suggest effects on variables associated with sensation.
Finney
Steven M
SM
Western General Hospital, Edinburgh, UK.
Andersson
Karl-Erik
KE
Gillespie
James I
JI
Stewart
Laurence H
LH
D006801:Humans; D018727:Muscarinic Antagonists / Q000627:therapeutic use*; D009119:Muscle Contraction / Q000187:drug effects*; D012678:Sensation Disorders / Q000503:physiopathology*; D014549:Urinary Incontinence / Q000188:drug therapy* / Q000503:physiopathology
D018727:Muscarinic Antagonists